SkinBioTherapeutics plc (FRA:5KW)

Market Cap	50.04M
Revenue (ttm)	3.24M
Net Income (ttm)	-3.11M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.1650
Previous Close	0.1660
Day's Range	0.1650 - 0.1700
52-Week Range	0.1420 - 0.3120
Beta	n/a
RSI	57.03
Earnings Date	Dec 2, 2025

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 2015
• Employees: 15
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5KW

Financial Performance

In 2024, SkinBioTherapeutics's revenue was 1.21 million, an increase of 815.26% compared to the previous year's 132,057. Losses were -2.88 million, 1.44% more than in 2023.

Financial numbers in GBP